5-氯-3-苯基-1,2,4-恶二唑 | 827-44-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-氯-3-苯基-1,2,4-恶二唑
• 中文别名: 5-氯-3-苯基-1,2,4-噁二唑
• 英文名称: 5-chloro-3-phenyl-1,2,4-oxadiazole
• 英文别名: 5-chloro-3-phenyl-[1,2,4]oxadiazole；3-phenyl-5-chloro-1,2,4-oxadiazole；3-Phenyl-5-chlor-1,2,4-oxadiazol；5-Chlor-3-phenyl-1,2,4-oxadiazol
• CAS: 827-44-1
• 化学式: C₈H₅ClN₂O
• mdl: MFCD09971531
• 分子量: 180.593
• InChiKey: MOJYPXFSJLVCRN-UHFFFAOYSA-N

物化性质

• 熔点：
  37-38℃
• 沸点：
  110 °C(Press: 15 Torr)
• 密度：
  1.328±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 储存条件：
  2-8℃

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 5-Chloro-3-Phenyl-1,2,4-Oxadiazole
: CBR01758
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 180,6 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
5-Chloro-3-Phenyl-1,2,4-Oxadiazole
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
5-Chloro-3-Phenyl-1,2,4-Oxadiazole
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-3-苯基-1,2,4-恶二唑 在 palladium on activated charcoal 氢气 作用下， 以 苯 为溶剂， 反应 1.0h， 生成 1-methyl-3-phenyl-Δ³-1,2,4-triazolin-5-one
  参考文献：
  名称：

  3-苯基-1,2,4-恶二唑-5-基肼的热行为

  摘要：

  根据在肼基部分的取代，3-苯基-1,2,4-恶二唑-5- ylhydrazines热解（1） - （5）给出了不同量的1-氨基- Δ的2 -1,2,4-三唑啉-5-酮（13）或（17），Δ 2 -或Δ 3 -1,2,4-三唑啉-5-酮（12），（18）或（19），并且š嗪（ 20）。讨论了一种可能的解释产品及其效果的机制。根据过氧化苯甲酰对反应的影响以及肼（1）–（4）催化加氢的行为，提出了双自由基中间体和氢从反应介质中的转移。

  DOI：

  10.1039/p19810001703
• 作为产物：
  描述：

  3-苯基-5-羟基-1,2,4-噁二唑 在 calcium chloride 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以32%的产率得到5-氯-3-苯基-1,2,4-恶二唑
  参考文献：
  名称：

  [EN] COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS ET UTILISATIONS DE CES DERNIERS

  摘要：

  本发明涉及对神经系统疾病治疗中有用的化合物。本发明的化合物，单独或与其他药用活性剂结合，可用于治疗或预防神经系统疾病。

  公开号：

  WO2018081167A1

文献信息

• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• [EN] CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS<br/>[FR] AZOLES TRIAZOLES D'ACIDE CYCLOHEXYLE UTILISÉS EN TANT QU'ANTAGONISTES DE LPA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019126094A1

  公开（公告）日：2019-06-27

  The present invention provides compounds of Formula (I): Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

  本发明提供了化合物的结构式（I）：结构式（I）或其立体异构体、互变异构体或药学上可接受的盐或溶剂，其中所有变量如本文所定义。这些化合物是选择性LPA受体抑制剂。
• [EN] N- CYCLOPROPYL - N- PIPERIDINYLBENZAMIDES AS GPR119 MODULATORS<br/>[FR] N-CYCLOPROPYL-N-PIPÉRIDINYLBENZAMIDES EN TANT QUE MODULATEURS DE GPR119
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012123449A1

  公开（公告）日：2012-09-20

  The present invention relates to compounds of general formula I, wherein the groups R1, LP, LQ, Ar, mand n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的化合物，其中基团R1、LP、LQ、Ar、m和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• New compounds, pharmaceutical compositions and uses thereof
  申请人：NOSSE Bernd

  公开号：US20130065906A1

  公开（公告）日：2013-03-14

  The present invention relates to compounds of general formula I, wherein the groups R 1 , L P , L Q , Ar, m and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的化合物， 其中基团R 1 ，L P ，L Q ，Ar，m和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• Reaktionen der substituierten 1,3,3-Trichloro-2-aza-propene [N-(1,1-Dichloro-alkyl)-imidchloride]
  作者：K. FINDEISEN、K. WAGNER、H. HOLTSCHMIDT

  DOI：10.1055/s-1972-21944

  日期：——

  Polychloro-2-azapropenes are readily accessible via high-temperature chlorination of alkyl isocyanide dichlorides, N-alkylimidoyl chlorides, and Schiff bases1. The present review surveys the synthetically useful reactions of the lowest representative of the series, pentachloro-2-azapropene (trichloromethyl isocyanide dichloride, TMI) and shows that the ring-closure reactions of this compound can also be carried out with the higher homologous 1,3,3-trichloro-2-azapropenes 1. Reactions of Trichloromethyl Isocyanide Dichloride (TMI) involving Cleavage of the Molecule 1.1. Hydrolysis of TMI 1.2. Intramolecular Dehydration by TMI 1.3. Reaction of TMI with Alcohols 1.4. Reaction of TMI with Carboxylic Acids 1.5. Reaction of TMI with Sulfonic Acids 2. Reaction of Trichloromethyl Isocyanide Dichloride (TMI) with Carbonyl Groups 2.1. Conversion of Aldehydes into 1,1-Dichloroalkanes 2.2. Conversion of Carboxylic Acid Anhydrides into the Acid Chlorides 3. Reactions of Trichloromethyl Isocyanide Dichloride (TMI) as a Carbonic Acid Derivative (Synthesis of Orthocarbonates) 3.1. Reaction of TMI with Monofunctional Phenols and Trichloroethanol 3.2. Reaction of TMI with Polyfunctional Phenols 4. Syntheses involving Incorporation of the C-3 Atom of Trichloromethyl Isocyanide Dichloride (TMI) or Substituted 1,3,3-Trichloro-2-azapropenes into N-Heterocyclic Compounds 4.1. Synthesis of 1,3,5-Triazines 4.2. Synthesis of Pyrimidines 4.3. Synthesis of Quinazolines 4.4. Synthesis of 1,2,4-Triazoles 4.5. Synthesis of 1,2,4-Oxadiazoles

  多氯-2-氮丙烯可通过高温氯化烷基异氰二氯化物、N-烷基亚胺基氯和席夫碱1来容易地获得。目前的综述调查了该系列中最低代表物五氯-2-氮丙烯（三氯甲基异氰二氯化物，TMI）的合成上有用的反应，并表明通过较高同系物的1,3,3-三氯-2-氮丙烯也可以进行环闭合反应。 1. 三氯甲基异氰二氯化物（TMI）的分子断裂反应 1.1. TMI的水解 1.2. TMI的分子内脱水 1.3. TMI与醇的反应 1.4. TMI与羧酸的反应 1.5. TMI与磺酸的反应 2. 三氯甲基异氰二氯化物（TMI）与羰基的反应 2.1. 醛转化为1,1-二氯烷烃 2.2. 羧酸酐转化为酰氯 3. 三氯甲基异氰二氯化物（TMI）作为碳酸衍生物的反应（正碳酸盐的合成） 3.1. TMI与单功能酚和三氯乙醇的反应 3.2. TMI与多功能酚的反应 4. 合成涉及将三氯甲基异氰二氯化物（TMI）或取代的1,3,3-三氯-2-氮丙烯的C-3原子并入N-杂环化合物 4.1. 1,3,5-三嗪的合成 4.2. 嘧啶的合成 4.3. 喹唑啉的合成 4.4. 1,2,4-三唑的合成 4.5. 1,2,4-噁二唑的合成